

PHARMACIST-LED OBSERVATIONAL STUDY ON QUALITY OF LIFE IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: EVIDENCES FROM THE QOSMOS STUDY

V. DAMUZZO¹, D. MENGATO², F. MILANI¹, L. AGNOLETTO³, N. FREDDI⁴, R. RAMPAZZO, N. REALDON¹

¹ School Of Hospital Pharmacy, Department Of Pharmaceutical And Pharmacological Sciences- University Of Padua, Padua, Italy.

² Bolzano General Hospital, Hospital Pharmacy, Bolzano, Italy.

³ Santa Maria Della Misericordia Hospital, Hospital Pharmacy, Rovigo, Italy.

⁴ Sant'Antonio Hospital - AULSS 6 Euganea, Department Of Neurology, Padua, Italy.

⁵ Health Department- Veneto Region, Coordinamento Settore Farmaceutica- Dispositivi E Protesica, Venice, Italy.

Background and Importance

Patient-reported outcomes (PRO) are increasingly used to evaluate effectiveness of treatments for Multiple Sclerosis (MS) and they often include an evaluation of health-related quality of life (QoL).

In 2017 the Italian Society of Clinical Pharmacy and Therapeutics (SIFaCT) and the National Association of Hospital Pharmacy Students (ReNaSFO) established a join action to update existing data on QoL and its correlation with use of disease-modifying drugs in Italian patients.

Results will be helpful as reference for future studies using PRO.

Aim and Objectives

✓ Primary endpoint was to measure QoL score in MS patients.


✓ Secondary objectives include correlation of QoL with pharmacological therapy and clinical characteristics of patients.

Materials and Methods




DESIGN

Observational, cross-sectional, multicentered




CRF

MS-QOL54
Clinical characteristics: sex, age, MS type, Expanded Disability Status Scale (EDSS), history of pharmacological treatments



FEASIBILITY


Ethic approval
Centre specific activities managed by students of Hospital Pharmacy School
Patient informed consent



STATISTICS



Spearman correlation test, Anova on ranks for multiple comparison and Mann-Whitney test for simple comparison.

N PATIENTS		N (%)
SEX	F	341 (100%)
	M	235 (68.9)
ETHNIC GROUP	CAUCASIAN	106 (31.1)
	ARAB	1 (0.3)
	MIXED	1 (0.3)
Age (median [range])		44 [19, 75]
DIAGNOSIS	RR-MS (Relapsing- remitting)	319 (93.5)
	SP-MS (Secondary progressive)	11 (3.2)
	RP-MS (Progressive relapsing)	3 (0.9)
	PP-MS (Primary progressive)	1 (0.3)
	OTHER demyelinating disease	7 (2.1)
Score EDSS (median [range])		1.50 [0.00, 7.00]
Number of relapses in last two years (median [range])		0.00 [0.00, 6.00]
Time from diagnosis (median [range])		6.85 [0.30, 34.22]



Results

- ✓ We enrolled 341 patients from 16 centres (median age 44.1 years; 68.9% women) with relapsing–remitting MS from May 2018 to June 2019
- ✓ Physical and mental well being were correlated with each other ($R=0.826$; $p<0.001$) according to a direct proportionality
- ✓ Both indexes had an inverse correlation with the degree of EDSS disability ($R=0.511$, $p<0.001$ and $R=0.344$, $p<0.001$, respectively).
- ✓ Patients treated with teriflunomide had lower physical QoL scores compared with patients treated with other oral drugs



A multiple linear regression analysis was calculated to predict QoL based on age, EDSS score and type of treatment.

Participant's Physical Health Composite Score decreased 7,36 points for each point of EDSS and 10,29 points in patients treated with teriflunomide ($R^2=35,08$, $p<0,001$)

Conclusion and Relevance

- ✓ The study achieved primary and secondary endpoints and indicated a relevant decrease in QoL related to physical health associated with teriflunomide, which deserves further investigations.
- ✓ We also demonstrated that joint action by a scientific society and a student association was a valuable method to perform a no profit, multicentre, observational study in real practice

Acknowledgements

Centre, Principal Investigator, Hospital Pharmacist Student
Azienda Socio Sanitaria Territoriale di Crema, Maria Teresa Ferrò, **Carolina Desiré Premoli**
Ospedali Riuniti Padova Sud - AULSS6 Euganea, Laura Agnoletto, **Silvia Michielan**
Fondazione Istituto G.Giglio di Cefalù, Ruscica Maria, **Simona Brocato**
Azienda Socio Sanitaria Territoriale Ovest Milanese, Luca Varalli, **Luca Cancanelli**
Ospedale Maria Vittoria Torino, Cinzia Boselli, **Regina Tarantini**
Ospedale San Giovanni Bosco di Torino, Leggieri Anna, **Stefano Costantino**
Ospedale Policlinico Maggiore - Milano, n.d., **Francesca Cammalleri**
Ospedale Sant'Antonio Padova, Michieli Mariangela, **Federica Milani**

Azienda Ospedaliera di Perugia, Alessandro D' Arpino, **Giuseppe Rizza**
Ospedale G. Mazzini ASL 4 di Teramo, Pasqualino Spinosi, **Chiara Di Sciascio**
Azienda Sanitaria Locale TO4 Ivrea, Elena Zinetti, **Laura Pestrin**
AUSL Piacenza - Ospedale "G. Da Saliceto", Simonetta Radici, **Corrado Confalonieri, Alessia Sartori**
I.R.C.C.S. Istituto Neurologico Carlo Besta, Anna Maria Fiori, **Valentina Marini**
Az. Ospedaliera Policlinico Universitario "G. Martino" Messina, Aliferopulos Harilaos, **Caterina De Stefano**
Ospedale Maggiore - AUSL Bologna, Lucia Alberghini, **Chiara Falesiedi**
Ospedale Santa Maria della Misericordia Rovigo - AULSS 5 Polesana, Laura Agnoletto, **Elena Pasquali**
Az. Ospedaliera Universitaria di Sassari, Demontis Stefania, **Chiara Altana, Stefano Cortese, Mauro Farina**



<https://www.eahp.eu/25-5PSQ-059>